EVA Pharma is proud to participate in this year’s DUPHAT UAE at its 2023 edition in Dubai, from 10-12th January.
We invite you to meet our team at hall 2 - stand 2D10.&nbsp;

medium_MicrosoftTeams-image (97).png

small_MicrosoftTeams-image (97).png

thumbnail_MicrosoftTeams-image (97).png

MicrosoftTeams-image (97).png

DUPHAT, UAE 2023

EVA Pharma is proud to announce our participation in the UN Climate Change Conference (COP27) in Sharm el-Sheikh. ​
We invite you to meet our team at hall A2 - booth H3; to discuss initiatives for a better climate for the next generations and sustainable development goals for local patients' needs. ​
&nbsp;
book a meeting: https://forms.office.com/r/vB4MBW5XXi&nbsp;&nbsp;

large_Cop 27 Wide copy.png

medium_Cop 27 Wide copy.png

small_Cop 27 Wide copy.png

thumbnail_Cop 27 Wide copy.png

Cop 27 Wide copy.png

      COP27- Sharm El Sheikh - Egypt 2022                                                     

EVA Pharma is proud to participate in this year’s CPHI , a global gathering that brings together pharmaceutical companies from around the world to discuss the latest industry trends and innovations.&nbsp;
&nbsp;
The event will be held in Frankfurt, Germany , from 1 – 3 November 2022 . Come meet EVA Pharma at 40C50

medium_MicrosoftTeams-image (18).png

small_MicrosoftTeams-image (18).png

thumbnail_MicrosoftTeams-image (18).png

MicrosoftTeams-image (18).png

CPHI - Frankfurt, Germany 2022 . 

<div class="OutlineElement Ltr SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif; font-weight: bold;" xml:lang="EN-US" data-contrast="auto">EVA<span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto"> <span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif; font-weight: bold;" xml:lang="EN-US" data-contrast="auto">Pharma<span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto"> is participating as a sponsor for the first time at the European Association for the Study of Diabetes’ (EASD) 2022 Annual Meeting, which will be held in Stockholm, Sweden, from 19 to 23 September.<span class="EOP SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="EOP SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559740&quot;:259}">&nbsp;
</div>
<div class="OutlineElement Ltr SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow: visible; cursor: text; clear: both; position: relative; direction: ltr; font-family: 'Segoe UI', 'Segoe UI Web', Arial, Verdana, sans-serif; font-size: 12px; background-color: #ffffff;">
<p class="Paragraph SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; overflow-wrap: break-word; white-space: pre-wrap; vertical-align: baseline; font-kerning: none; background-color: transparent; color: windowtext;"><span class="TextRun SCXW200050207 BCX9" lang="EN-US" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-variant-ligatures: none !important; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" xml:lang="EN-US" data-contrast="auto">The EASD holds its Annual Meeting in a different European city each year, with more than 15,000 delegates from over 130 countries attending. The scientific program at this year’s 58th Annual Meeting includes more than 1,200 talks and presentations on the latest results in diabetes research by leading experts in the field.<span class="EOP SCXW200050207 BCX9" style="margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; font-size: 11pt; line-height: 19.425px; font-family: Calibri, Calibri_EmbeddedFont, Calibri_MSFontService, sans-serif;" data-ccp-props="{&quot;201341983&quot;:0,&quot;335559740&quot;:259}"> 
</div>

European Association for the Study of Diabetes’ Annual Meeting 2022 

medium_MicrosoftTeams-image (160).png

small_MicrosoftTeams-image (160).png

thumbnail_MicrosoftTeams-image (160).png

MicrosoftTeams-image (160).png

European Association for the Study of Diabetes’ Annual Meeting 2022             

EASD  Annual Meeting 2022 

Happening at EVA Pharma

EVA Pharma’s roots in Egypt stretch back over a hundred years.

Our History

Our experienced leadership team keeps us on track.

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

Life at EVA Pharma

Meet EVA Pharma's global team at the 4th Annual Patient Experience Conference from the 6th to 8th of November 2023 at Riyadh, Saudi Arabia. Definitely, It will be a great opportunity to share knowledge, discovering local patients unmet needs, and innovating to treat their sufferings.

Event

large_MicrosoftTeams-image (51).png

medium_MicrosoftTeams-image (51).png

small_MicrosoftTeams-image (51).png

thumbnail_MicrosoftTeams-image (51).png

MicrosoftTeams-image (51).png

Patient Experience Conference, KSA , EVAPharma for   discovering local patients unmet needs, 

Meet our global team at the Patient Experience Conference 

Eva Pharma is excited to announce its participation in EASD 2023 for the second consecutive year. As a leading pharmaceutical company committed to advancing diabetes care, we are thrilled to showcase our latest innovations at the event. We invite you to visit our booth at location C.07, where we will present our wide range solutions and engage in insightful discussions to further enhance diabetes management and empower the fight for patient health and well-being as a human right.&nbsp; EASD 2023 , Date: 2nd -6th of October, Place: Hamburg, Germany, Location of booth: C.07.

large_MicrosoftTeams-image (54).png

medium_MicrosoftTeams-image (54).png

small_MicrosoftTeams-image (54).png

thumbnail_MicrosoftTeams-image (54).png

MicrosoftTeams-image (54).png

EVA Pharma's Participation in EASD 2023 in Hamburg, Germany

EVA Pharma's Participation in EASD 2023

We Empower the Fight for Health and Well-being Globally. EVA Pharma launches a novel treatment “Evaneotrim” for the treatment of obesity in Egypt. The experts praised the launch of this medication, and their insights clarified that the medicine will be a promising step towards obesity control in the country.

EVA Pharma launches a novel treatment “Evaneotrim” for the treatment of obesity in Egypt.

medium_for website event size .jpg

small_for website event size .jpg

thumbnail_for website event size .jpg

for website event size .jpg

EVA Pharma launches a novel treatment “Evaneotrim” for the treatment of obesity in Egypt

EVA Pharma launches a novel treatment “Evaneotrim”

large_news website size copy (1).jpg

medium_news website size copy (1).jpg

small_news website size copy (1).jpg

thumbnail_news website size copy (1).jpg

news website size copy (1).jpg

In partnership with MODON, EVA Pharma to invest in an industrial complex  in Saudi Arabia

Cairo, 8 June, 2023 –
Roche, the leading Swiss pharmaceutical company, and EVA Pharma, a global healthcare organization that focuses on unmet patient needs, announced today a strategic partnership to localize the production of advanced medication for patients undergoing organ transplant procedures. The MOU includes localizing manufacturing at EVA Pharma’s dedicated and internationally accredited immunosuppressant manufacturing facility in 10th of Ramadan city, Egypt as well as the prospect of exporting to emerging markets in Africa.
&nbsp;
The official MoU signing event was held at the 2nd edition of the Africa Health Excon and was witnessed by&nbsp; Dr. Awad Tag Eldin, Presidential advisor for health affairs; Major General Dr. Bahaa El Din Ahmed Zeidan, Chairman of the Egyptian Authority for Unified Procurement; Dr. Tamer Essam, Head of the Egyptian Drug Authority;&nbsp; Prof. Dr. Adel Adawy – Former Minister of Health and Population, Egypt; Mr. Andreas Muller, Regional Area Finance Director Middle East in Roche as well as the Swiss Embassy’s Deputy Head of Mission, Ms. Elisabeth Gilge. The agreement was signed by Dr. Mohamed Swilam, General Manager of Roche Egypt and Dr. Riad Armanious, CEO of EVA Pharma.
&nbsp;
This manufacturing localization project will encourage technology transfer and the complicated know-how development of much-needed immunosuppressant&nbsp; medication&nbsp; which is essential to improve the lives of patients who are undergoing organ transplants via a cost-competitive and resilient model, deepening local pharmaceutical production in alignment with the Egyptian government’s priorities. The pharmaceutical industry is a major pillar of Egypt’s economic reform plan in terms of the value of its contribution to GDP and the creation of job opportunities and ultimately supports the achievement of the country’s sustainable development strategy, Egypt's Vision 2030.
&nbsp;
“Roche has a very patient-centric approach and is committed to improving the outcomes that matter most to patients across the entire care journey,” said Dr. Swilam. “This MoU will enable us to deliver innovative medication to Egyptian patients faster and at an economic cost and this is the core outcome we are aiming to achieve. This manufacturing localization project encourages technology transfer and local knowledge development which enables a more sustainable health care system, and helps in establishing strategic national capabilities to unleash the country's future potential in the field of health care.”
&nbsp;
The MoU signing and localization demonstrates Roche as a proven strategic partner with the expertise, experience, and technological leadership to help deliver the Egyptian Government’s Health Pillar of its 2030 Vision.
&nbsp;
“Although we are still in an early stage within the industry transformation journey, I believe we are now living in one of the best times of healthcare provision in Egypt in terms of positive change, appreciation of the value of innovation, and genuine interest from decision makers to improve patients’ lives.” Swilam added.
&nbsp;
“We believe that the availability of high-quality medicines is crucial. Patients undergoing organ transplant procedures require special care, starting with the quality of the medications they receive.” Said Dr. Armanious, CEO of EVA Pharma. “Our collaboration with Roche will bring innovative and high-quality medicines to those in need. By leveraging cutting-edge technological advancements, we aim to reduce the impact of pre- and post-transplant issues, ultimately improving patient outcomes. With our robust operational capabilities and our dedicated immunosuppressant manufacturing site we will significantly reduce lead times in making these health care solutions available for patients in emerging markets.”
&nbsp;
Dr. Armanious added, “The pharmaceutical industry in Egypt has reached important and advanced stages of quality, comparable to international standards in the industry, and the MoU we are signing today is a testament to that. We are very proud to be able to not only bring this advanced technology to Egypt but to other emerging markets across Africa as well. This is why we are eager to collaborate with Roche and reach the ultimate goal of increasing patient access to life-saving medicines”.
&nbsp;
About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalized healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relEVAnt stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of
Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&amp;D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
&nbsp;
&nbsp;
&nbsp;
About EVA Pharma
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
&nbsp;
For more information, please visit: www.EVApharma.com &amp; https://www.EVApharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram.&nbsp;&nbsp;
&nbsp;
&nbsp;

large_MicrosoftTeams-image (209).png

medium_MicrosoftTeams-image (209).png

small_MicrosoftTeams-image (209).png

thumbnail_MicrosoftTeams-image (209).png

MicrosoftTeams-image (209).png

EVA Pharma and Roche sign a strategic partnership

EVA Pharma and Roche announce a Strategic Partnership to Manufacture Advanced Technology Medication in Egypt

CAIRO – May 30, 2023 – EVA Pharma is celebrating the completion of its new biologics’ facility in Cairo, which is set to start producing high-quality insulin next month as part of an ongoing collaboration with Eli Lilly and Company to expand sustainable access to the essential medical product.
In a first for both companies, EVA Pharma and Lilly entered a novel agreement December 2022 in which Lilly supplies its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma, along with a pro-bono technology transfer.&nbsp;
“The completion of this state-of-the-art facility is a critical milestone on the path to provide high-quality, affordable insulin in Egypt and throughout Africa. With a production capacity of 90 million vials and 50 million cartridges, we will eventually reach at least one million people annually in low- to middle-income countries,” said Riad Armanious, EVA Pharma’s CEO.
"We are committed to transforming healthcare in Africa and the Middle East by localizing the manufacturing of life-saving treatments like insulin. With the inauguration of our biologics’ facility, we are proud to be at the forefront of this effort. This is not only vital for the long-term sustainability of healthcare systems but also for empowering local communities and building more resilient healthcare infrastructure. We believe that high-quality and affordable medicines should be accessible to every patient in need, and we are honored to work with Lilly to make this a reality," he added.
Ahead of submitting for prequalification from the World Health Organization (WHO), EVA Pharma’s Cairo-based manufacturing line is now set to undergo inspection by the Egyptian Drug Authority. Once the inspection is completed, EVA Pharma expects to start the production of this African-made insulin by end of July 2023"
“Lilly congratulates EVA Pharma for completion of its new biologics’ facility, which represents a significant leap forward on the journey to expand access to insulin for millions of people in Africa,” said Ilya Yuffa, executive vice president and president of Lilly International, who toured the new biologics’ facility in Cairo on the day of celebration.
Approximately 24 million adults living in Africa currently suffer from diabetes, according to recent estimates from the International Diabetes Federation (IDF), with that number predicted to grow. In 2021, WHO launched its Global Diabetes Compact in order to galvanize action on diabetes prevention and control. The Compact supports agreements like the one between EVA Pharma and Lilly, recognizing that such collaborations are necessary to ensure sustainable access to high-quality medicines in low and middle-income countries.
About EVA Pharma
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram&nbsp;&nbsp;
&nbsp;

large_MicrosoftTeams-image (162).png

medium_MicrosoftTeams-image (162).png

small_MicrosoftTeams-image (162).png

thumbnail_MicrosoftTeams-image (162).png

MicrosoftTeams-image (162).png

EVA Pharma Completes New Biologics Facility as Part of Insulin Collaboration with Lilly

&nbsp;
CAIRO – May 22, 2023 -- EVA Pharma participated in the 76th World Health Assembly (WHA) side event on the role of local manufacturing in improving access to noncommunicable disease (NCD) medicines. The event, held on May 22nd in Geneva, served as an influential platform to address the paramount issues surrounding medication accessibility. Among the pivotal points emphasized during the panel discussion was the urgent need for streamlining registration processes and implementing harmonized medicines registration systems to minimize delays and ensure swift access to life-saving medications for those in need.
&nbsp;
The panel discussion addressed the escalating burden of diabetes mellitus (DM) in Africa, where 24 million adults are currently living with DM according to the International Diabetes Federation (IDF). With projections estimating that 55 million people in Africa will have diabetes by 2045, the region is facing the largest increase in diabetes rates globally, as highlighted by the World Health Organization (WHO).
Access to affordable insulin remains a key barrier to successful treatment, resulting in unnecessary complications and premature deaths. In response to this critical issue, EVA Pharma started a collaboration with Eli Lilly and Company in December 2022 to expand sustainable access to high-quality, affordable human and analogue insulin and reach annually at least one million people living with type 1 and type 2 diabetes in 56 low- and middle-income countries (LMICs), most of which are in Africa.&nbsp;
&nbsp;
“We strive to save and improve millions of lives by offering accessible, high-value medicines and healthcare solutions that address local patients’ needs”, emphasized Dr. Riad Armanious, CEO of EVA Pharma. “By joining forces of all health advocates and taking synergistic actions we can implement real change. When we enhance regional manufacturing capabilities, we ensure that high-quality medicine reaches the patients who need it the most.”
&nbsp;
&nbsp;
The panel also featured esteemed panelists such as Dr. Bente Mikkelsen, Director of the NCD Programme at the World Health Organization (WHO), Ms. Loren Becker, Senior Director of Global Health Policy at Eli Lilly and Company, Dr. Rogerio Gaspar, Director of the Regulation and Prequalification Department at WHO, and Dr. Jean Kaseya, Director General of the Africa CDC.
&nbsp;
Keynote speakers at the event included H.E. Dr. Khaled Abdel Ghaffar, the Minister of Health and Population of Egypt, and Loyce Pace, Assistant Secretary of Health and Human Services for Global Affairs of the United States.
&nbsp;
EVA Pharma's participation in this WHA side event demonstrates its commitment to improving access to NCD medicines and its proactive role in fostering partnerships to address healthcare challenges in Africa. The company's dedication to meeting the needs of local communities aligns with the global effort to enhance healthcare systems and ensure that life-saving treatments reach all who require them.
&nbsp;
About EVA Pharma
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on LinkedIn&nbsp;&nbsp;
&nbsp;
Media Contact:&nbsp;
Ahmed Ellewa | Public Relations Head | ahmed.ellewa@evapharma.com | +20-1000-053-643
&nbsp;

large_MicrosoftTeams-image (161).png

medium_MicrosoftTeams-image (161).png

small_MicrosoftTeams-image (161).png

thumbnail_MicrosoftTeams-image (161).png

MicrosoftTeams-image (161).png

EVA Pharma Highlights Commitment to Improving Access to NCD Medicines at the 76th WHA Side Event on Role of Local Manufacturing

Cairo,5th March
Oncology experts hail moves to manufacture cancer treatments locally
Oncology professors participating in last month’s 14th International Conference of the Department of Oncology and Nuclear Medicine at the Faculty of Medicine, Assiut University, praised the steps taken by some Egyptian pharmaceutical companies to localize oncology drug manufacturing within the country.
Dr. Samir Shehata, professor of oncology at the Faculty of Medicine, Assiut University, commented: “We encourage all Egyptian companies to enter the field of manufacturing oncology drugs, to provide medicine in a sustainable way and at low prices.”
He added, in his statements on the sidelines of the conference, that presidential campaigns and initiatives have led to a decrease in death rates among oncology patients, but this decrease requires continuity in the provision of treatments, which represents a great burden on the state.
Dr. Ibtisam Saad El-Din, professor of oncology at the Faculty of Medicine, Cairo University, said that the production of oncology drugs within Egyptian factories will create a perpetual supply at an affordable price. She explained that such drugs are used in the treatment of many tumors. This includes advanced breast cancer, especially the hormone-positive type, which represents about 75% of breast cancer cases among women.
She pointed out that the treatments are manufactured inside Egypt by an Egyptian company with the same efficiency and at a lower cost than imported medicine.
Dr. Mohamed Abdel Moaty, professor of oncology and hematology at the National Institute of Cancer at Cairo University, said that multiple myeloma a rare form of cancer, representing 2% of tumors in general and 10% of tumors of the blood. It is treated via a number of directed and immune drugs.
He explained that there are 160,000 cases of multiple myeloma worldwide, with an incidence rate of 1 per 100,000 people. In Egypt, 800 cases are diagnosed annually, at approximately the same rate as the global level, and the accumulated cases number about 1,700.
Dr. Raafat Abdel-Fattah, professor of hematology and bone marrow transplantation at the National Institute of Cancer at Cairo University, said that Egypt manufactures around 90% of the &nbsp;medicines it needs. In the field of tumors and malignant blood diseases, the country imports about 95% of its drug needs, he added, so localizing the manufacture of oncology drugs and medicines for malignant blood diseases is a breakthrough in the treatment of these diseases.
He added that providing modern treatments such as lenalidomide in Egypt is the best option for treating blood diseases such as bone marrow cancer or multiple myeloma.
Dr. Hisham Tawfik, professor of oncology at the Faculty of Medicine, Tanta University, said that the localization of the pharmaceutical industry to Egypt is in line with the state's sustainable development efforts and Egypt's 2030 strategy.
He added that the localization of the pharmaceutical industry to Egypt has three benefits, namely continuity in the provision of medicines, provision of medicines at low prices, and a reduction in pressure on forex reserves.
Dr. Amjad Talaat, General Manager of the Specialized Medicines Unit at EVA Pharma, said that the company is working to provide the latest medicines, in cooperation with the MARC Center for Scientific Research and with international firms. In doing so, EVA Pharma is contributing to the localization of the pharmaceutical industry to Egypt, he said.
Dr. Talaat noted that the company has recently moved towards manufacturing targeted drugs and immunosuppressants and has allocated a factory to produce these drugs, as well as oncology and blood disease medications. The facility, which operates using the latest international technology, ensures continuity in provision of these medicines to consumers in Egypt, or in other Arab or African countries, with the highest efficiency and at an appropriate price.

large_MicrosoftTeams-image (146).png

medium_MicrosoftTeams-image (146).png

small_MicrosoftTeams-image (146).png

thumbnail_MicrosoftTeams-image (146).png

MicrosoftTeams-image (146).png

Oncology experts hail moves to manufacture cancer treatments locally.

Cairo,3rd of Feb2023&nbsp;
The Egyptian Association for Urology Research, in cooperation with the Supreme Council of University Hospitals and the Egyptian Medical Association, and sponsored by EVA Pharma, has launched the second edition of the Egyptian guidelines for the treatment of urological diseases, a critical area of specialization.
Dr. Mohamed Awad Taj El-Din, presidential adviser for health affairs, stressed the importance of putting in place national guidelines and guidelines for various medical specialties that help patients obtain the best medical care.
He said that establishing guidelines for various diseases ensure the optimal use of antibiotics in terms of type and duration, helping prevent antibiotic resistance. He added that the Egyptian Society of Chest Diseases and Tuberculosis has set guidelines for respiratory infections.
Dr. Sherif Murad, professor of urology at Ain Shams University and rapporteur for the Egyptian Urology Guidelines Committee, said that the committee began work in November 2019, as a result of the efforts of the Egyptian Urology Association and the Supreme Council of University Hospitals, with the support of the Egyptian Medical Association. Formed by a decree from Dr. Khaled Abdel Ghaffar, then minister of higher education and scientific research, the committee includes a number of specialized academics among its members and has 14 sub-committees.
Murad said that the first edition of the guidelines was launched in 2021 to serve as a reference for urologists and others for whom it would be relevant, include those working on cancer or male infertility.
The committee continues to update the guidelines periodically, in line with international medical trends, and to keep abreast of updates in the specialty, Murad said, so that the guidelines retain their value.
The goal of the committee at this stage is to unify the guidelines in the various health facilities affiliated with different authorities and ministries in all governorates, he added, in order to ensure equality between patients and to improve recovery rates.
Dr. Muhammad Shalaby, professor of urology, said that although there are international guidelines in the specialty of urology, some of them are not commensurate with the medical capabilities available at health facilities
Many surgeries abroad currently depend on the use of robots and modern endoscopes, he said, and these capabilities are not available in some Egyptian establishments, especially in the areas outside Cairo.
The nature of urinary tract diseases is different in Egypt than abroad due to climatic conditions and the spread of some diseases, Shalaby also said. For example, there are some cases of kidney stones among children as young as 6 months old.
He noted that the launch of the second edition of the urological guidelines was attended by more than 100 doctors.
The committee also sought the assistance of expert Alaa Ghoneimi, professor of pediatric surgery at the University of Paris, he said.
Shalaby also praised the efforts of EVA Pharma, an Egyptian pharmaceutical company which provides Egyptian patients with treatments of high quality and at reasonable prices.
For his part, Dr. Rafiq Al-Halabi, professor of urology at the Faculty of Medicine at Ain Shams University, said that the existence of guidelines for dealing with urological cases is beneficial for patients, both at the diagnosis and treatment stages.
The guidelines are also beneficial for doctors, allowing them to provide the most appropriate treatment methods in each case, preventing potential professional mistakes and exposure to legal risk.
He emphasized that the results of the publication of the first version of the guidelines was very good, and many young doctors working in the specialty sought help from the publication. The second version was the result of an integrated effort over months to include everything that is part of the specialty, with the addition of infections, testicular cancers and adrenal gland diseases.
Al-Halabi said that kidney stones, kidney and bladder cancer, and prostate enlargement are among the most common diseases of the urinary tract among men, and that the incidence of prostate tumors, both benign and malignant, increases over the age of 50.

large_MicrosoftTeams-image (132).png

medium_MicrosoftTeams-image (132).png

small_MicrosoftTeams-image (132).png

thumbnail_MicrosoftTeams-image (132).png

MicrosoftTeams-image (132).png

launch of the second edition of Egypt’s urology guidelines 

medium_MicrosoftTeams-image (99).png

small_MicrosoftTeams-image (99).png

thumbnail_MicrosoftTeams-image (99).png

MicrosoftTeams-image (99).png

“Hyatk Mkmla” campaign

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries
&nbsp;
INDIANAPOLIS and CAIRO,&nbsp; December 14, 2022 – Eli Lilly and Company (NYSE: LLY) and EVA Pharma&nbsp; announced today a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.
&nbsp;
In a first for Lilly, the company will supply its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma. Lilly will also provide a pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges – establishing the company as a trusted manufacturer of these lifesaving products in Africa.
&nbsp;
EVA Pharma expects to begin distribution of the African-made insulin products within 18 months and to reach one million people per year by 2030. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality healthcare for 30 million people living in limited -resource settings, annually, by 2030
&nbsp;
“Our new collaboration with EVA Pharma reflects Lilly’s deep commitment to making equitable and affordable access to insulin a reality for people living with diabetes in low- and middle-income countries,” said Ilya Yuffa, president of Lilly International. “This latest initiative from Lilly will empower&nbsp; local manufacturing, finishing and&nbsp; distribution of quality insulin – in Africa – which will transform communities and make life better for people throughout the continent.”
&nbsp;
“EVA Pharma is committed to empowering the fight for health and well-being as a human right,” said Riad Armanious, CEO of EVA Pharma. “People suffering from diabetes in LMICs experience daily challenges in accessing treatment. We feel blessed to collaborate with the team at Lilly. Combining our African reach, state-of-the-art facilities, and Lilly’s deep expertise in diabetes care, we aim to treat at least one million patients by 2030 who otherwise may not have access to life-saving medication.”
&nbsp;
According to the IDF Diabetes Atlas, the total number of people with diabetes in Africa is expected to increase 129% by 2045, reaching 55 million people.
&nbsp;
&nbsp;
&nbsp;
&nbsp;WHO established the Global Diabetes Compact in 2021, a global initiative to support countries in implementing effective programs for the prevention and management of diabetes, one tenet of which includes engaging with the private sector to expand access to products that will improve the lives of people living with diabetes. The dialogues with WHO encourage implementation of and accountability for the commitments and contributions toward improving access to insulin
&nbsp;
“The success of these commitments to increase access for people living with diabetes is an important step in the right direction, but global engagement will need to be translated into implementation in regions and countries,” said WHO Director for Noncommunicable Disease, Dr Bente Mikkelsen. “This is the starting point the hope is to have insulin and diabetes devices as part of Essential Benefit Packages in low- and middle- income countries towards achieving Universal Health Coverage.”
&nbsp;
&nbsp;
&nbsp;
Lilly will work with EVA Pharma to ensure that their products meet the high-quality standards set for WHO prequalification, which has become a global symbol for safety, quality and efficacy.
&nbsp;
&nbsp;
&nbsp;
&nbsp;About Lilly&nbsp;
&nbsp;
&nbsp;
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram and LinkedIn.
About EVA Pharma
EVA Pharma empowers the fight for health and well-being in communities around the world.
With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram&nbsp;&nbsp;
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about a collaboration between Lilly and EVA Pharma and its potential benefits and reflects Lilly’s current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, that the collaboration will succeed, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
&nbsp;

large_MicrosoftTeams-image (68).png

medium_MicrosoftTeams-image (68).png

small_MicrosoftTeams-image (68).png

thumbnail_MicrosoftTeams-image (68).png

MicrosoftTeams-image (68).png

 Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa

large_pexels-kaboompics-com-6335@2x.png

medium_pexels-kaboompics-com-6335@2x.png

small_pexels-kaboompics-com-6335@2x.png

thumbnail_pexels-kaboompics-com-6335@2x.png

pexels-kaboompics-com-6335@2x.png

Are you a Journalist or Media Representative and need information about us? Please feel free to get in touch with our PR Team

© 2022 Eva Pharma All Rights Reserved - شركة ايفا فارما للادوية و المستلزمات الطبية